Sus Clinicals, Inc.

From Jessicca R., CEO: How often do we wish we could have a better animal model to predict what will happen in the clinic? We at Sus Clinicals are building a platform of preclinical models all based on the amazing similarity between the pig and the human.?This was confirmed via the foundational pig genome mapping effort led by our CSO and co-founder Lawrence Schook. (Read more about this work in the comment below.) Our Oncopig??enables researchers to induce tumors with?controlled?timing and development to test therapeutics, devices, and diagnostics.?We can gather predictive data, answering key preclinical testing?questions of metabolism, safety and EFFICACY, in one animal model. Take a look at the 2 minute video below to learn more about our platform. Reach out and we are happy to provide more information and become the animal model of choice for your next project.

Reflections from Jessicca R.: My first 90 days as CEO at Sus Clinicals... What a wonderful whirlwind of an experience these first few months have been for me as the new CEO of Sus Clinicals. The first?90 days are sometimes the most important in building relationships, setting culture and establishing a clear vision for the Company’s success, and no matter how much homework and research you put into evaluating a company you just don't know until you start. As a first time CEO, I was scared and excited all at the same time. It reminds me of when I first became a parent.?What do you do with this amazing precious "gift" that you are now responsible for -- ensuring they become the best human being they can be, but you yourself are still evolving to your best self.?The endless worry, the stress, the sleepless nights, the financial juggling, setting expectations, difficult conversations, and navigating each delicate interaction as they transition through?the stages of life. I am still working on being a better mom to my son who is now 16 (and a great baseball player), and I think my adventure as the CEO of Sus Clinicals will be a constant evolution as well. No journey is worth taking without the risk.? I joined Sus Clinicals because this is a company that truly wants to help innovate the science needed to build better research platforms, starting with our Oncopig?.?The value we are creating for our customers is real. The ability to have a large animal platform suitable for testing efficacy, safety, metabolic effects, and more, is game changing.?With our Oncopig we can induce tumors and comorbidities in real time, helping researchers test novel cancer-fighting therapeutics, devices, and diagnostics.? As an innovator we are continuing to build even better solutions, to enable researchers to move their life-saving treatments into the clinic faster and more efficiently, while reducing the overall risk. We all know within R&D the limitations around translating animal research to humans in the clinic, but Sus Clinicals is on the cutting edge of making this a reality. Reach out if you would like to hear more about my journey.?I am happy to share more on how Sus Clinicals can help you move your research programs forward.?

We are delighted that Jessicca Rege is joining Sus Clinicals, Inc. as our next CEO.? ? Dr. Rege brings deep scientific expertise and a demonstrated track record of cross-functional business and scientific leadership, from start-ups to major global pharmaceutical players.? ? ?“I am thrilled to be joining the Sus Clinicals team,” said Dr. Rege.?“My passion is to accelerate transformative research and therapeutics into the clinic, with the hope to save lives. To bring the qualified and FDA cleared Oncopig? platform to more researchers across the industry including medical devices, diagnostics and pharmaceuticals is a wonderful opportunity professionally and for the patients we all serve.”? ? Most recently Dr. Rege was Chief Development Officer of Mural Oncology and was instrumental in leading the public offering of the company.?Prior to Mural she served as VP, Head of Clinical Development, Oncology at Alkermes.?Over her career she has held positions with increasing responsibility in leading organizations including research and development, regulatory, operations, manufacturing, along with impressive track records in business development, M&As and fundraising.?She has held multiple leadership roles in larger pharmaceuticals companies, all with significant oncology portfolios, including Daiichi Sankyo US, Eli Lilly and Company and Eisai US, to name a few.??? “Dr. Rege’s educational background, with a Ph.D. in Pharmaceutical Sciences specializing in pharmacogenomics, her extensive pharmaceutical experience, and her superb leadership skills all position her well to take Sus Clinicals to the next level,” said Jeff Weedman, Board Chair and Co-Founder of the Company. Sus Clinicals accelerates development of?life-saving cancer therapeutics through proprietary pig-based pre-clinical testing services.?Known as the Oncopig Cancer Model?, this highly predictive approach can more quickly identify drugs, diagnostics and devices that have the highest potential for success in human clinical trials.?

Lawrence Schook opened today's #SBR2024 by sharing his reflections on progress since the first Swine in Biomedical Research conference in 1995. Looking ahead, Larry encouraged the group to continue efforts to create porcine biomedical research models even more reflective of human diseases, phenotypes, etc. We at Sus Clinicals, Inc. along with our many academic and industry collaborators are proud to play a role in helping accelerate life saving therapeutics "from bench to bedside."

We at Sus Clinicals, Inc. are delighted to participate in this year's Swine in Biomedical Research Conference #SBR2024, hosted by University of Wisconsin-Madison at their beautiful lakeside campus. Hundreds of the world's leading experts in porcine-based research will convene for the next four days to share their latest learnings to help advance breakthrough biomedical therapeutics. We are proud to be a sponsor of #SBR2024.

We're delighted that Dr. Kyle Schachtschneider, VP of R&D/Services, will present updates on our Oncopig Cancer Model? at next week's Society of Interventional Radiology Annual Meeting #SIR24SLC. This includes our liver and lung cancer models for device-based therapeutic studies, as well as a liver radioembolization study, co-presented with Dr. Aravind Arepally of ABK Biomedical Inc. This Sus Clinicals, Inc. team is proud to be working with remarkable cancer researchers in their mission to accelerate breakthrough therapeutics, to help save lives. ?

Sus Clinicals, Inc. announced today that Dr. Lawrence Schook has been elected to the Company’s Board of Directors. ? “I’m delighted that my friend and co-founder has joined the Board,” said Jeff Weedman, Co-Founder, CEO and Chair, Board of Directors. “I recall vividly when I met Larry, and he told me of the work he and his University of Illinois Urbana-Champaign team were doing to accelerate cancer research with a novel preclinical porcine model. We both saw the potential not only to create a company together, but to help cancer researchers save lives.” ? Sus Clinicals accelerates qualification of life-saving cancer therapeutics through proprietary pig-based pre-clinical testing services, the Oncopig Cancer Model?. ? “I’m honored to be joining the Board” said Dr. Schook. “Our whole team has made such tremendous progress since we stood up the Company in 2020. With FDA clearance and growing experience with our Oncopig? platform, I’m excited to continue our efforts to scale this capability broadly.” ? In addition to Weedman, remaining on the Board are Geoffrey Marshall, CFO, and Steve Baggott, COO. Marshall and Baggott lead the Company’s commercial operations, and are based in Cincinnati, Ohio. Most of the Company’s scientific and technical team is based in facilities at the University of Illinois Chicago Incubator Laboratory Facility, where the bulk of the Company’s research is conducted. ? In his role as a leader in the porcine research space, Dr. Schook led the global team which sequenced the pig genome in 2012. This work led to important foundational knowledge that supported the creation of the Oncopig Cancer Model.? ? Dr. Schook currently serves on the Albion College Board of Trustees, where he is a member of the executive committee and co-chairs the People and Talent Committee.

We are delighted that Kyle Schachtschneider, Vice President of R&D and Services for Sus Clinicals, Inc. will present exciting research from the Oncopig Cancer Model? at the Society of Interventional Oncology Annual Meeting later this month. Entitled “The Oncopig hepatocellular carcinoma (HCC) model as a tool for locoregional therapeutic studies,” Dr. Schachtschneider will share this research on Sunday, January 28 during presentations beginning at 3:30pm. HCC is an aggressive disease, often with a poor prognosis. Locoregional therapies (LRTs) are widely used for liver cancer treatment, and large animal models can support evaluation of new LRTs. The Oncopig Cancer Model is an ideal platform for such research, with induction of HCC on demand, yielding tumors virtually indistinguishable from their human counterparts, just two weeks post induction. As such, the Oncopig provides an ideal bridge between early mouse-based research and expensive human trials, helping cancer researchers move promising new therapies to the clinic faster. Dr. Schachtschneider, a widely published expert on the pig as a biomedical research platform, and other Sus Clinicals representatives will be at SIO and available for discussions with attendees who may be interested in learning more about Oncopig-based capabilities. Or contact us at [email protected].